Evelo Biosciences
Cambridge
About Evelo Biosciences
Evelo Biosciences is dedicated to improving the lives of patients globally through the development of a new modality of medicines – monoclonal microbials. Monoclonal microbials are orally delivered medicines that modulate systemic immunology and biology through direct interactions with human cells in the gut. These new medicines are broadly applicable across many diseases – including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory diseases, and cancer. Monoclonal microbials have the potential to fundamentally change traditional models of drug discovery and development. By finding and selecting naturally occurring monoclonal microbial with defined therapeutic effects, Evelo can improve the speed, cost, and success of drug discovery and development. Evelo’s platform enables pharmacological intervention at all stages of the disease with naturally occurring, safe, and effective monoclonal microbials. Evelo Biosciences was conceived and created within VentureLabs®, Flagship Pioneering’s institutional innovation foundry, and launched by Flagship in 2015.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $397.0M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jul 2023)
- Ticker: nasdaq:EVLO
- Website: evelobio.com
- Phone: +1 617 577 0300
Industries & Categories
Biotechnology, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/evelo-biosciences-29640 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.